Press Release / Media Release
Zydus receives tentative approval from the USFDA for Abacavir and Lamivudine Tablets USP08-08-2017
08-08-2017
Zydus Cadila gets US FDA nod to market anti-dementia drug
Zydus Cadila today said it has received final nod from the US health regulator to market Memantine Hydrochloride extended-release capsules used for the treatment of dementia of Alzheimer's type....05-08-2017
Press Release
Zydus receives final approval from the USFDA for Memantine Hydrochloride Extended-Release Capsules05-08-2017
Zydus gets USFDA nod for brain tumour, hyper tension drugs
Cadila Healthcare Ltd (Zydus Cadila) has received final approval from the USFDA to market Temozolomide capsules in strengths of 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, and 250 mg. Temozolomide...01-08-2017
Press Release
Zydus receives final approval from the USFDA for Temozolomide Capsules and Nadolol Tablets USP.01-08-2017
Post Results [Q1 2017-2018 April To June 2017] Q&A; Session Through Teleconference Has Been Scheduled On August 11, 2017 At 4:30 P.M.
As per the attached letter.01-08-2017
Zydus Cadila gets USFDA approval for colitis drug; margins get a boost
Currently, it sells the authorised generic version of Asacol HD in the US25-07-2017
Press Release
'Zydus receives final approval from USFDA for Mesalamine Delayed Release Tablets, 800 mg'.25-07-2017
Updates
Please find attached herewith the copies of the advertisement of Notice of Twenty Second Annual General Meeting, E-voting and Book Closure information published in the English and Gujarati editions of Financial Express on July 21, 2017 for the perusal of your good office.21-07-2017
Zydus launches ulcer drug in US; gets FDA nod for haemophilia drug
Cadila Healthcare Ltd (Zydus Cadila), on Wednesday, said it has commercially launched the Mesalamine delayed release tablet USP, for the treatment of mild to moderate ulcerative colitis, in the US...19-07-2017